Welcome to our dedicated page for Pharmather Holdings news (Ticker: PHRRF), a resource for investors and traders seeking the latest updates and insights on Pharmather Holdings stock.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) specializes in developing novel ketamine-based therapies and advanced drug formulations for critical healthcare needs. This news hub provides investors and healthcare professionals with essential updates on the company's clinical programs, regulatory milestones, and strategic initiatives.
Access timely updates on KETARX™ clinical trials, FDA correspondence regarding ketamine production, and developments in PD-001 formulation research through Sairiyo Therapeutics. Our curated news collection covers earnings announcements, partnership agreements, manufacturing updates, and therapeutic application discoveries.
Key areas of focus include progress in addressing global anesthesia shortages, advancements in mental health treatment research, and quality control enhancements in pharmaceutical production. The resource serves as a centralized tracking tool for monitoring the company's progress through clinical development phases and regulatory review processes.
Bookmark this page for streamlined access to verified updates about PharmaTher's work in pain management innovation and neurological disorder research. Regularly updated content ensures stakeholders maintain current understanding of the company's position within the competitive pharmaceutical landscape.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) announced an update regarding its KETARX™ (ketamine) treatment for levodopa-induced dyskinesia in Parkinson's disease, following a Type C meeting with the FDA. The FDA supported the company's regulatory approach and indicated that a single confirmatory trial could suffice for marketing approval under specific conditions. PharmaTher will adjust its clinical development plans according to the FDA's feedback and aims to pursue FDA Fast Track designation. Recent Phase I/II results showed ketamine was safe and well-tolerated, with significant reductions in dyskinesias for all subjects treated.
FAQ
What is the current stock price of Pharmather Holdings (PHRRF)?
What is the market cap of Pharmather Holdings (PHRRF)?
